Pharmaceutical company · ALPMY

Astellas Pharma
clinical trial
pipeline

Registry checked

Published

Oncology is the largest mapped primary therapeutic group, with 34 of 58 active trials. This ranking covers mapped groups only. zolbetuximab is linked to 7 distinct active studies, with 1 Phase 1, 2 Phase 2, 3 Phase 3, 1 Phase 4. Enfortumab vedotin is linked to 5 distinct active studies, with 2 Phase 2, 2 Phase 3, 1 Phase 4.

Phase 2 study NCT03816163 in Pancreatic Cancer and Metastatic Pancreatic Cancer lists estimated primary completion on 31 October 2026. Phase 2 study NCT06792435 in Pancreatic Adenocarcinoma Metastatic and Lung Cancer (NSCLC) lists estimated primary completion on 30 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

58active trials
as lead sponsor
  • Phase 116
  • Phase 217
  • Phase 313
  • Phase 43
  • Phase not recorded9

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

01 Oct 2026 – 30 Oct 2026 · UTC

Recorded changes

1812 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved earlier by 61 days

2028-12-31 (estimated)2028-10-31 (estimated)
31 Dec 202831 Oct 2028

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

NCT07339267 · ClinicalTrials.gov
Recorded by ComplyRx
27 Oct 2026
Registry last updated
26 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-010000000
2026-10-021000011
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-081000011
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-131110252
2026-10-141010021
2026-10-150100011
2026-10-160100011
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-200100121
2026-10-210010121
2026-10-220000000
2026-10-230000111
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270100011
2026-10-280000000
2026-10-290000000
2026-10-300000000
Type totals553051812 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

zolbetuximab

vyloy

7
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 11
  • Phase 22
  • Phase 33
  • Phase 41
  • Phase not recorded0
Studied condition
Gastric Cancer · Gastro-esophageal Junction (GEJ) Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Next primary completion
31 October 2026 · estimated
Open drug

Enfortumab vedotin

padcev · padcevejfv

5
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 22
  • Phase 32
  • Phase 41
  • Phase not recorded0
Studied condition
Locally Advanced or Metastatic Malignant Solid Tumors · Metastatic Urothelial Carcinoma · Muscle-invasive Bladder Cancer
Next primary completion
Not reported
Open drug

Fezolinetant

VEOZAH

4
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded1
Studied condition
Hot Flashes · Prostate Cancer
Next primary completion
Not reported
Open drug

Setidegrasib

Canonical investigational asset

4
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy Volunteer · Metastatic Pancreatic Adenocarcinoma · Metastatic Pancreatic Cancer
Next primary completion
Not reported
Open drug

Emaretamig

Canonical investigational asset

3
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Gastric Adenocarcinoma · Gastroesophageal Junction (GEJ) Adenocarcinoma · Pancreatic Adenocarcinoma
Next primary completion
Not reported
Open drug

enzalutamide

xtandi

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Metastatic Hormone Sensitive Prostate Cancer · Prostate Cancer
Next primary completion
Not reported
Open drug

45 of 58 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 45 of 58 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Astellas Pharma trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
zolbetuximab

NCT03816163

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

Start clipped at the display horizon.

1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

Up to three verified eligible observations in the bounded history window.

  • pc date moved · Recorded 2026-10-15 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 15 Mar 2019 · actual
Primary completion: 31 Oct 2026 · estimated
Study completion: 31 Oct 2026 · estimated

2021202220232024202520262027202820292030
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
XNW27011

NCT06792435

Phase 2 · Active, not recruiting

Trial source and qualifications

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

2 candidate observations · 2 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

Up to three verified eligible observations in the bounded history window.

  • status flip · Recorded 2026-08-12 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • pc date moved · Recorded 2026-08-12 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 27 Jul 2023 · actual
Primary completion: 30 Dec 2026 · estimated
Study completion: 30 Jun 2027 · estimated

2021202220232024202520262027202820292030
ILUSTRO
zolbetuximab

NCT03505320

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 5 inspected observations were not displayed.

Start clipped at the display horizon.

6 candidate observations · 1 shown · 0 recorded after primary completion · 5 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

5 inspected observations omitted. At most three verified observations are shown, not full history.

  • pc date moved · Recorded 2026-09-01 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 29 Jun 2018 · actual
Primary completion: 30 Jun 2027 · estimated
Study completion: 31 May 2028 · estimated

2021202220232024202520262027202820292030
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Roxadustat

NCT05970172

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

  • status flip · Recorded 2026-10-14 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • enrollment change · Recorded 2026-10-14 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 16 Jan 2024 · actual
Primary completion: 30 Oct 2027 · estimated
Study completion: 30 Oct 2027 · estimated

2021202220232024202520262027202820292030
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
Methylprednisolone

NCT07052929

Phase 2 · Recruiting

Trial source and qualifications

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 15 Dec 2025 · actual
    Primary completion: 31 Oct 2027 · estimated
    Study completion: 31 Oct 2027 · estimated

    2021202220232024202520262027202820292030
    A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
    Enfortumab vedotin

    NCT07475806

    Phase 2 · Recruiting

    Trial source and qualifications

    A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

    Duration ends at independently recorded study completion. Source date qualifications: end-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    End clipped at the display horizon.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 12 Mar 2026 · actual
      Primary completion: 30 Nov 2027 · estimated
      Study completion: 30 Apr 2031 · estimated

      2021202220232024202520262027202820292030

      Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

      6 selected of 19 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 7 actual primary completions, 0 untyped primary completions, 0 past estimates, 4 outside the horizon, 0 contradictory dates.

      04 / Therapeutic focus

      Where the activity is

      34

      active trials in Oncology

      Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

      Active trials by primary therapeutic area

      • Oncology34 trials
      • Ophthalmology5 trials
      • Womens Health3 trials
      • Metabolic/Endocrine/Nutrition2 trials
      • Renal & Urology2 trials
      • Immunology & Inflammation1 trials
      • Neurology1 trials
      • Unmapped8 trials
      • Healthy volunteers2 trials

      Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

      06 / Related companies

      All companies
      P

      Pfizer

      Shared indexed programme context · 1 selected asset

      Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

      Sources, scope and methodology

      ClinicalTrials.gov lead-sponsor scope

      Canonical current-owner attribution covers 980 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Astellas Pharma. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

      ClinicalTrials.gov

      Attribution coverage

      980 distinct registry candidates produced 980 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

      Indexed enrichment

      888 scoped records have indexed enrichment and 92 do not. Missing enrichment does not remove a trial from cohort counts.

      Scope observation

      The successful attribution check completed at 2026-10-31T23:34:04.722Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 909abfef78fb3b38f392d93cd88e25c91d00748010f5029675726dc7e721a1f1.

      Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

      Dated canonical-attribution snapshot: 980 mapped lead-sponsored clinical studies across all statuses. 888 have indexed enrichment, 92 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

      Keep following
      what matters.

      Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

      Build your watch

      Choose what to track in the watch builder.